ROCEPHIN PWS 1GM/VIAL POWDER FOR SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

متاح من:

HOFFMANN-LA ROCHE LIMITED

ATC رمز:

J01DD04

INN (الاسم الدولي):

CEFTRIAXONE

جرعة:

1G

الشكل الصيدلاني:

POWDER FOR SOLUTION

تركيب:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 1G

طريقة التعاطي:

INTRAMUSCULAR

الوحدات في الحزمة:

10 ML IV

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

THIRD GENERATION CEPHALOSPORINS

ملخص المنتج:

Active ingredient group (AIG) number: 0117292003; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2011-10-17

خصائص المنتج

PRODUCT MONOGRAPH
ROCEPHIN
®
(sterile ceftriaxone sodium)
0.25, 1 g ceftriaxone per vial
Antibiotic
Hoffmann-La Roche Limited
Date of Preparation:
2455 Meadowpine Boulevard
June 16, 1987
Mississauga, Ontario
L5N 6L7
www.rochecanada.com
Date of Revision:
February 9, 2010
Control Number: 134328
®
Registered Trademark of Hoffmann-La Roche Limited
©
Copyright 1987-2010, Hoffmann-La Roche Limited
ROCEPHIN
®
„ PAGE 3
PRODUCT
MONOGRAPH
ROCEPHIN
®
(Sterile Ceftriaxone Sodium)
0.25, 1 g ceftriaxone per vial
Antibiotic
ACTION
_In vitro _studies indicate that the bactericidal action of
ceftriaxone results from the inhibition of
cell-wall synthesis. In E.coli
, ceftriaxone showed a high affinity for penicillin binding proteins
(PBP) 1a and 3 and a moderate affinity for 1b and 2. In H. influenzae,
the highest affinity was
shown for PBP 4 and PBP 5. The binding affinity to PBP 4 was 35-fold
that of PBP 3, 10-fold
that of PBP 2 and approximately 100-fold that of PBP 1. The
morphological changes resulting
from the PBP binding include filament formation or cell wall and
septal thickening, and then cell
lysis.
INDICATIONS AND CLINICAL USES
The treatment of the following infections when caused by susceptible
strains of the designated
micro-organisms:
Lower Respiratory tract infections
caused by E. coli, H. influenzae, K. pneumoniae and species,
Staph. aureus, Strep. pneumoniae and species (excluding enterococci).
Urinary tract infections (complicated and uncomplicated) caused by E.
coli, Klebsiella species,
P. mirabilis and P. vulgaris.
Bacterial Septicemia caused by E. coli, H. influenzae, K. pneumoniae,
Staph. aureus and
Strep.
pneumoniae, (excluding enterococci).
Skin and Skin Structure Infections caused by K. pneumoniae and
species, P. mirabilis,
Staph. aureus, Staph. epidermidis and Streptococcus species (excluding
enterococci).
Bone and Joint Infections caused by Staph. aureus, Strep. pneumoniae
and Streptococcus
species (excluding enterococci).
Intra-Abdominal Infections caused by E.coli and K. pneumoniae.
Meningitis c